atHeart Medical
Private Company
Total funding raised: $30M
Overview
atHeart Medical is a clinical-stage medical device innovator targeting the structural heart disease market with its novel reSept™ ASD Occluder. The device's key differentiator is its metal-free frame, aiming to set a new standard of care by minimizing the permanent implant footprint and reducing potential long-term complications like erosion, while not limiting future transseptal interventions. The company is currently advancing its pivotal ASCENT ASD IDE trial in the US and internationally, backed by an experienced leadership team and foundational support from its Swiss corporate founder.
Technology Platform
Metal-free frame platform for transcatheter structural heart devices, designed to minimize permanent implant footprint and preserve future treatment options.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
The ASD occluder market is dominated by large players like Abbott (Amplatzer) and Occlutech, which offer metal-based devices. atHeart Medical's primary competitive advantage is its novel metal-free design, positioning it as a potential disruptor targeting specific patient subgroups underserved by current technologies.